Screening refers to tests and exams used to find a disease, such as cancer, in people who do not have any symptoms. Breast cancers found during screening exams are more likely to be smaller and still confined to the breast. One of these products is the SensorySuite. Breast Cancer Awareness month has tried to highlight the importance of attending breast screenings in detecting breast cancer as early as possible. Breast Cancer Awareness month aims to highlight the importance of attending breast screenings in detecting breast cancer as early as possible and increasing the chances of successfully managing and treating spotting and cancer disease.
The size of a breast cancer and how far it has spread are some of the most important factors in predicting the prognosis of a woman spotting and cancer this disease. Survival rates are improving in developed countries but there is still a lot of improvement needed in poor resourced countries. Many women present with stage III or IV disease which sometimes requires toddler constipation and antibiotics and expensive chemotherapies.
Improved outcomes for breast cancer are more likely to happen when affordable screening, surgery and treatment are available. Today there are approximately 17, GE Healthcare mammography systems in use worldwide. Despite the screening coverage that digital mammography technology provides, the fears that women experience when notified of a breast screening may cause some of them to delay or postpone their appointment.
Claire Goodliffe believes these fears are based on a lack of information about the screening process, spotting and cancer, which has become much more patient-friendly in recent times, spotting and cancer.
I think the most uncomfortable thing about it is the compression of the breast which typically lasts only twenty seconds. As insights into cancer deepen and discoveries about this disease are made every day one can only imagine the direction treatments and therapies will take in order to take advantage of this knowledge.
Goodliffe believes that there will be an increased use of companion diagnostics that can better determine the efficacy of chemotherapy. GEHC can play a role to monitor therapies and provide clinicians with valuable information to help them manage their patients, spotting and cancer. More and more hospitals are providing genetic testing services and risk assessments that can identify whether a woman is carrying a genetic mutation.
They can also provide diagnostic spotting and cancer to determine if she is more likely to respond to a specific treatment. The Pulse is a new online magazine covering news around healthcare, technology, innovation and science created by GE Healthcare. The site focuses on four topics: The Pulse will also showcase industry partnerships that support the vision of increased access, quality and affordability of healthcare spotting and cancer the world.
GE Healthcare is not responsible for this service.